Core Viewpoint - The stock price of ShuoDi Bio has been on a continuous decline despite recent positive developments, indicating a disconnect between market performance and company fundamentals [1][2][4]. Stock Performance - As of February 13, 2026, ShuoDi Bio's stock closed at $71.25, down 1.10% for the day, with a cumulative decline of 4.90% over the past five days and a price fluctuation of 14.82%, reaching a low of $70.05 [1]. - The trading volume showed significant variation, with a peak of $64.05 million on February 12 (turnover rate of 1.24%) and a drop to $21.96 million on February 13 (volume ratio of 1.08) [1]. - The biotechnology sector rose by 1.84%, but ShuoDi Bio's performance lagged behind the broader market, which saw the Nasdaq index decline by 1.54% [1]. Recent Events - On December 30, 2025, ShuoDi Bio entered a non-exclusive patent licensing agreement with Roche and Genentech, receiving a $100 million upfront payment and the right to earn low single-digit royalties on future sales of Genentech's oral GLP-1 drug CT-996 [2]. - This partnership does not restrict the company's core pipeline development and provides non-dilutive funding support, yet the stock price has not reflected this positive news [2]. Financial Analysis - For the third quarter of 2025, ShuoDi Bio reported zero revenue and a net loss of $65.8 million, with a return on equity (ROE) of -25.31%, indicating ongoing pressure on short-term profitability due to R&D investments [3]. - The company has a debt-to-asset ratio of 7.47% and a current ratio of 14.15%, suggesting a solid financial structure despite significant profitability gaps [3]. Institutional Perspectives - Multiple brokerages remain optimistic about ShuoDi Bio's long-term value, primarily due to the cash flow potential from the patent collaboration and the scarcity of the oral GLP-1 pipeline [4]. - However, short-term stock performance is constrained by sector rotation, technical corrections, and market concerns regarding increased competition in the GLP-1 space, leading to significant funding divergence [4].

Summary of Key Points from the Conference Call on China's Healthcare Industry and Emerging Oral GLP-1 Pipelines Industry Overview - The report focuses on the **emerging oral GLP-1 pipeline** within the **China healthcare industry** and discusses the potential market size exceeding **$45 billion** [1][8][14]. Core Insights and Arguments - The global oral GLP-1 market is projected to peak between **$45 billion and $75 billion**. Recent clinical data from leading companies indicate that emerging pipelines still have opportunities for market entry [8][14]. - Over **20 oral GLP-1 candidates** from Chinese biopharmaceutical companies are in development, with most retaining global rights. This suggests significant potential for future licensing and partnerships [8][18]. - Companies such as **Hengrui/Kailera**, **Huadong Medicine**, and **Regor Therapeutics** are leading in clinical progress and data maturity, with several key catalytic events expected in the next six months [8][18]. - The emerging pipeline is diverse, including candidates from **Hansoh Pharmaceutical**, **China Biologic Products**, **Sino Biopharma**, and several private companies [8][18]. - Variations in patient baseline characteristics and dose escalation strategies complicate direct data comparisons across clinical trials. Other critical factors include data integrity for indications beyond obesity, scalability of production, and patent reviews [8][18]. Additional Important Insights - The oral GLP-1 market is evolving towards a more fragmented competitive landscape, contrary to the previously expected oligopolistic structure. Recent clinical results from leading candidates suggest new entry opportunities for emerging pipelines [15][18]. - The report outlines the competitive landscape and potential collaboration opportunities, highlighting that the U.S. biopharma sector is actively seeking partnerships with Chinese companies due to the evolving market dynamics [18][20]. - The report includes a detailed table of oral GLP-1 candidates, their development phases, and licensing status, providing a comprehensive overview of the competitive landscape [3][20]. Conclusion - The oral GLP-1 market presents a significant opportunity for both established and emerging players, particularly from China. The evolving clinical data and competitive dynamics suggest a promising future for innovative therapies in this space [8][14][15].